Study of Metformin to Slow the Growth of Abdominal Aortic Aneurysms in Adults Aged 50 to 95

What this Trial Is About

Researchers are evaluating the effects of the drug metformin on the growth of abdominal aortic aneurysms AAAs, which are abnormal enlargements of the large artery in the abdomen that risk rupturing and causing life-threatening bleeding. This Phase 2 trial aims to determine whether metformin can prevent AAAs from growing larger, building on smaller studies that suggested metformin may slow the enlargement of these aneurysms. Participants are randomly assigned to take either metformin tablets or identical placebo tablets daily. The dosage of metformin is gradually increased over the first four weeks, starting with one pill and increasing by one pill each week up to a maximum of four pills per day. If side effects occur, the dose is lowered to the highest tolerated amount. This dosing continues throughout the study, which includes two years of follow-up. During the study, participants will undergo computed tomographic aortography CTA scans at the beginning and end to measure the size of the aneurysm. Researchers will monitor changes in the aortas size, track adherence to the medication, and assess other health outcomes including cardiovascular events, mortality, medication changes, and blood markers related to liver, kidney, and blood function. Surveys about living with AAA and general health will also be collected. The study lasts for two years, with ongoing safety and health assessments throughout.

Limiting AAA With Metformin (LIMIT) Trial